500 related articles for article (PubMed ID: 25490234)
41. ProTargetMiner as a proteome signature library of anticancer molecules for functional discovery.
Saei AA; Beusch CM; Chernobrovkin A; Sabatier P; Zhang B; Tokat ÜG; Stergiou E; Gaetani M; Végvári Á; Zubarev RA
Nat Commun; 2019 Dec; 10(1):5715. PubMed ID: 31844049
[TBL] [Abstract][Full Text] [Related]
42. Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery.
Erlanson DA; Arndt JW; Cancilla MT; Cao K; Elling RA; English N; Friedman J; Hansen SK; Hession C; Joseph I; Kumaravel G; Lee WC; Lind KE; McDowell RS; Miatkowski K; Nguyen C; Nguyen TB; Park S; Pathan N; Penny DM; Romanowski MJ; Scott D; Silvian L; Simmons RL; Tangonan BT; Yang W; Sun L
Bioorg Med Chem Lett; 2011 May; 21(10):3078-83. PubMed ID: 21459573
[TBL] [Abstract][Full Text] [Related]
43. Current compound coverage of the kinome.
Hu Y; Furtmann N; Bajorath J
J Med Chem; 2015 Jan; 58(1):30-40. PubMed ID: 25051177
[TBL] [Abstract][Full Text] [Related]
44. Identification and characterization of new inhibitors of fungal homoserine kinase.
De Pascale G; Griffiths EJ; Shakya T; Nazi I; Wright GD
Chembiochem; 2011 May; 12(8):1179-82. PubMed ID: 21538764
[No Abstract] [Full Text] [Related]
45. Mapping of inhibitors and activity data to the human kinome and exploring promiscuity from a ligand and target perspective.
Hu Y; Kunimoto R; Bajorath J
Chem Biol Drug Des; 2017 Jun; 89(6):834-845. PubMed ID: 27933727
[TBL] [Abstract][Full Text] [Related]
46. Comprehensive analysis of three-dimensional activity cliffs formed by kinase inhibitors with different binding modes and cliff mapping of structural analogues.
Furtmann N; Hu Y; Bajorath J
J Med Chem; 2015 Jan; 58(1):252-64. PubMed ID: 25054653
[TBL] [Abstract][Full Text] [Related]
47. Structure-based tailoring of compound libraries for high-throughput screening: discovery of novel EphB4 kinase inhibitors.
Kolb P; Kipouros CB; Huang D; Caflisch A
Proteins; 2008 Oct; 73(1):11-8. PubMed ID: 18384152
[TBL] [Abstract][Full Text] [Related]
48. Approval heralds new generation of kinase inhibitors?
Fletcher L
Nat Biotechnol; 2001 Jul; 19(7):599-600. PubMed ID: 11433254
[No Abstract] [Full Text] [Related]
49. Protein kinase inhibitors: insights into drug design from structure.
Noble ME; Endicott JA; Johnson LN
Science; 2004 Mar; 303(5665):1800-5. PubMed ID: 15031492
[TBL] [Abstract][Full Text] [Related]
50. New affinity probe targeting VEGF receptors for kinase inhibitor selectivity profiling by chemical proteomics.
Ku X; Heinzlmeir S; Helm D; Médard G; Kuster B
J Proteome Res; 2014 May; 13(5):2445-52. PubMed ID: 24712744
[TBL] [Abstract][Full Text] [Related]
51. Towards the chemoinformatic-based identification of DNA methyltransferase inhibitors: 2D- and 3D-similarity profile of screening libraries.
Yoo J; Medina-Franco JL
Curr Comput Aided Drug Des; 2012 Dec; 8(4):317-29. PubMed ID: 22734709
[TBL] [Abstract][Full Text] [Related]
52. Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery.
Seo SY
Arch Pharm Res; 2012 Feb; 35(2):197-200. PubMed ID: 22370774
[TBL] [Abstract][Full Text] [Related]
53. Protocols for the Design of Kinase-focused Compound Libraries.
Jacoby E; Wroblowski B; Buyck C; Neefs JM; Meyer C; Cummings MD; van Vlijmen H
Mol Inform; 2018 May; 37(5):e1700119. PubMed ID: 29116686
[TBL] [Abstract][Full Text] [Related]
54. Targeting Histone Acetyltransferase MOZ/KAT6A as a New Avenue for Hematological Tumor Therapy.
Zhou C; Zhu HL; Duan Y
Curr Top Med Chem; 2020; 20(5):333-335. PubMed ID: 32242512
[No Abstract] [Full Text] [Related]
55. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
[TBL] [Abstract][Full Text] [Related]
56. ATP-noncompetitive CDK inhibitors for cancer therapy: an overview.
Abate AA; Pentimalli F; Esposito L; Giordano A
Expert Opin Investig Drugs; 2013 Jul; 22(7):895-906. PubMed ID: 23735075
[TBL] [Abstract][Full Text] [Related]
57. Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): An update of recent medicinal chemistry efforts.
Ma X; Lv X; Zhang J
Eur J Med Chem; 2018 Jan; 143():449-463. PubMed ID: 29202407
[TBL] [Abstract][Full Text] [Related]
58. Structure-based and property-compliant library design of 11β-HSD1 adamantyl amide inhibitors.
Paderes GD; Dress K; Huang B; Elleraas J; Rejto PA; Pauly T
Methods Mol Biol; 2011; 685():191-215. PubMed ID: 20981525
[TBL] [Abstract][Full Text] [Related]
59. Deal watch: Bristol-Myers Squibb and Exelixis collaborate on kinase inhibitors.
Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180098
[No Abstract] [Full Text] [Related]
60. Small-molecule kinase-inhibitor target assessment.
Kung C; Shokat KM
Chembiochem; 2005 Mar; 6(3):523-6. PubMed ID: 15696508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
